Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Benzinga Newsdesk www.benzinga.com Negative 92.0%

Neg 92% Neu 0% Pos 0%

Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.